VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2021 | Treatments for patients with NSCLC carrying EGFR exon 20 insertions

Robin Cornelissen, MD, PhD, Erasmus University Rotterdam, Rotterdam, Netherlands, discusses the efficacy of treatments for patients with non-small cell lung cancer (NSCLC) carrying exon 20 insertions in the EGFR gene. Although they are not as efficacious as other targeted therapies, drugs targeting exon 20 insertions reduce disease burden and have increased progression-free survival (PFS) for this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter